# Vladimir Coric

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vladimir-coric/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,958 |
| Field | Migraine and Headache Studies |
| h-index | 42 |
| i10-index | 78 |
| Last Known Institution | Biohaven Pharmaceuticals (United States) |
| OpenAlex ID | https://openalex.org/A5069362203 |
| Works | 166 |

## Researcher papers

- [A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder](https://scholariq.org/papers/a-systematic-review-antipsychotic-augmentation-with-treatment-refractory/)
- [Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine](https://scholariq.org/papers/rimegepant-an-oral-calcitonin-gene-related-peptide-receptor-antagonist-for/)
- [Genome-wide association study of obsessive-compulsive disorder](https://scholariq.org/papers/genome-wide-association-study-of-obsessive-compulsive-disorder/)
- [Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial](https://scholariq.org/papers/efficacy-safety-and-tolerability-of-rimegepant-orally-disintegrating-tablet-for/)
- [Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease](https://scholariq.org/papers/safety-and-tolerability-of-the-secretase-inhibitor-avagacestat-in-a-phase-2/)
- [Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/oral-rimegepant-for-preventive-treatment-of-migraine-a-phase-2-3-randomised/)
- [Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture](https://scholariq.org/papers/partitioning-the-heritability-of-tourette-syndrome-and-obsessive-compulsive/)
- [Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial](https://scholariq.org/papers/riluzole-augmentation-in-treatment-resistant-obsessive-compulsive-disorder-an/)
- [Systematic Review: Pharmacological and Behavioral Treatment for Trichotillomania](https://scholariq.org/papers/systematic-review-pharmacological-and-behavioral-treatment-for-trichotillomania/)
- [Targeting Prodromal Alzheimer Disease With Avagacestat](https://scholariq.org/papers/targeting-prodromal-alzheimer-disease-with-avagacestat/)
- [Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States](https://scholariq.org/papers/real-world-assessment-of-the-relationship-between-migraine-related-disability/)

## Researcher topics

- [Migraine and Headache Studies](https://scholariq.org/topics/migraine-and-headache-studies/)
- [Obsessive-Compulsive Spectrum Disorders](https://scholariq.org/topics/obsessive-compulsive-spectrum-disorders/)
- [Traumatic Brain Injury Research](https://scholariq.org/topics/traumatic-brain-injury-research/)
- [Neurotransmitter Receptor Influence on Behavior](https://scholariq.org/topics/neurotransmitter-receptor-influence-on-behavior/)
- [Treatment of Major Depression](https://scholariq.org/topics/treatment-of-major-depression/)

## Researcher university

- [Biohaven Pharmaceuticals (United States)](https://scholariq.org/institutions/biohaven-pharmaceuticals-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.